INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.54
-0.41 (-5.90%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.95
Open7.00
Bid6.60 x 1100
Ask6.67 x 800
Day's Range6.50 - 7.04
52 Week Range4.10 - 15.02
Volume836,523
Avg. Volume566,195
Market Cap482.71M
Beta2.22
PE Ratio (TTM)N/A
EPS (TTM)-3.16
Earnings DateAug 1, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • This Pot Stock's First-Quarter Report Is Creating All the Wrong Buzz
    Motley Fool6 days ago

    This Pot Stock's First-Quarter Report Is Creating All the Wrong Buzz

    This potential turnaround candidate is still headed in the wrong direction.

  • The Wall Street Journal6 days ago

    [$$] U.S. Joins Whistleblower Suits Against Opioid Maker

    Its ex-chief executive officer, John Kapoor, and several former top executives have been charged with conspiracy to illegally distribute Subsys, a mouth-spray form of fentanyl that is approved by the Food and Drug Administration to treat cancer-related pain. Mr. Kapoor has denied wrongdoing and pleaded not guilty. Shares of Insys fell 6% on Tuesday.

  • Reuters6 days ago

    Insys sees no change in estimated litigation costs

    Insys Therapeutics Inc said on Tuesday that it believed a previously estimated $150 million would be sufficient to cover expenses from an ongoing litigation related to the company's sales practises. The news comes a day after the U.S. Department of Justice joined a whistleblower lawsuit alleging Insys paid kickbacks to doctors. The company continues to have an ongoing dialogue with the DOJ regarding this investigation, Insys said on Tuesday.

  • GlobeNewswire6 days ago

    INSYS Therapeutics Responds to Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation Efforts

    In December 2013, INSYS received a subpoena from the Office of Inspector General (OIG) of the Department of Health and Human Services (HHS), which notified the company of the commencement of an investigation by the DOJ’s Civil Division into the company’s sales and commercial practices and resulted in the company’s corresponding public disclosure. As is often the case, this four-and-a-half-year investigation has been conducted in concert with certain whistleblower litigation that was filed under seal prior to and during the course of the DOJ’s investigation.

  • Reuters7 days ago

    U.S. joins whistleblower case against Insys over kickbacks

    The U.S. Department of Justice has joined whistleblower litigation accusing Insys Therapeutics Inc of trying to generate more profit by paying kickbacks to doctors to prescribe powerful opioid medications. It adds firepower to the civil litigation as Insys tries to resolve a federal probe into its marketing of Subsys, a spray form of fentanyl. Six U.S. states - California, Colorado, Indiana, New York, North Carolina and Virginia - also joined whistleblower litigation against Insys, according to the filing in U.S. District Court in Los Angeles.

  • Reuters7 days ago

    U.S. joins lawsuits against opioid maker Insys over kickback scheme

    The U.S. Department of Justice has joined lawsuits accusing Insys Therapeutics Inc of paying kickbacks to doctors to prescribe a powerful opioid medication, in an effort to generate more profit. According to a filing made public on Monday in Los Angeles federal court, the department and six U.S. states intervened in whistleblower litigation against Insys, which has said it had been trying to negotiate a settlement of a federal probe into its marketing of fentanyl-based Subsys. The litigation followed a wave of related criminal cases against medical practitioners and former executives and sales representatives employed by Chandler, Arizona-based Insys, including its billionaire founder John Kapoor.

  • Thomson Reuters StreetEvents10 days ago

    Edited Transcript of INSY earnings conference call or presentation 8-May-18 9:00pm GMT

    Q1 2018 INSYS Therapeutics Inc Earnings Call

  • Why Marijuana Stock Insys Therapeutics Inc. Gained 16.1% in April
    Motley Fool11 days ago

    Why Marijuana Stock Insys Therapeutics Inc. Gained 16.1% in April

    Shares of the small-cap biotech climbed following news that the company would proceed with inhalation-based dronabinol delivery tests.

  • I Was Flat-Out Wrong About This Marijuana Stock
    Motley Fool13 days ago

    I Was Flat-Out Wrong About This Marijuana Stock

    Insys Therapeutics continues to flounder with no rebound in sight.

  • Associated Press13 days ago

    Insys Therapeutics: 1Q Earnings Snapshot

    The Chandler, Arizona-based company said it had a loss of 28 cents per share. Losses, adjusted for non-recurring costs and stock option expense, came to 19 cents per share. The results matched Wall Street ...

  • GlobeNewswire13 days ago

    INSYS Therapeutics Announces Exclusive License Partnership with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that it has agreed to an exclusive license partnership with Lunatus for commercialization of SUBSYS® (fentanyl sublingual spray) in the Middle East. Based in Dubai with satellite offices across the Gulf Cooperation Council, Lunatus will be the exclusive licensee for SUBSYS® in Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and the United Arab Emirates. “Partnering with Lunatus will make SUBSYS® available to adult cancer patients in the licensed territory who are suffering episodes of breakthrough cancer pain despite receiving around-the-clock opioid therapy,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics.

  • GlobeNewswire13 days ago

    INSYS Therapeutics Reports First Quarter 2018 Results

    Cannabinoid and spray-technology focused pipeline continues to advance, while efforts to stabilize SUBSYS ® revenue continue. PHOENIX, May 08, 2018-- INSYS Therapeutics, Inc., a leader in the development, ...

  • Investopedia19 days ago

    Top 4 Marijuana Stocks to Watch

    California joined the list of states to legalize recreational marijuana use at the start of 2018, and the markets are showing some enthusiasm for stocks related to the controversial plant. Attorney General Jeff Sessions is set to rescind an Obama-era rule of federal non-interference in state marijuana law enforcement. Currently, nine states and the District of Columbia have legalized recreational marijuana, while the substance is legal for medical purposes in 29 states. The rush to get in on the marijuana craze has created hundreds of startups, but the odds are that many of these will fail.

  • GlobeNewswire20 days ago

    New Research: Key Drivers of Growth for SecureWorks, Ingles Markets, Insys Therapeutics, Energous, XO Group, and Forward Air — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, May 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SecureWorks ...

  • ACCESSWIRE21 days ago

    Blog Exposure - INSYS Commences Phase-2 Clinical Trial of Cannabidiol Oral Solution for Treatment of Prader-Willi Syndrome

    Stock Monitor: Innoviva Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 01, 2018 / Active-Investors.com has just released a free research report on INSYS Therapeutics, Inc. (NASDAQ: INSY ) ("INSYS"). ...

  • GlobeNewswire25 days ago

    INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) for Treatment of Prader-Willi Syndrome

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, recently initiated a Phase 2 clinical trial of its cannabidiol (CBD) oral solution for evaluation of safety and efficacy in pediatric patients with Prader-Willi syndrome, a rare genetic disease characterized by insatiable appetite in children that often leads to obesity, type 2 diabetes and premature death. Prader-Willi syndrome is the most common genetic cause of obesity that has been identified, affecting upwards of 400,000 people worldwide, according to epidemiological research.

  • GlobeNewswire26 days ago

    INSYS Therapeutics and University of California (UC) San Diego Center for Medicinal Cannabis Research to Collaborate on Clinical Trial

    NSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced a collaboration with the University of California (UC) San Diego School of Medicine’s Center for Medicinal Cannabis Research (CMCR) to study cannabidiol (CBD) as a potential treatment for severe symptoms of autism in pediatric patients. INSYS has agreed to provide its pharmaceutical-grade CBD oral solution—already under clinical evaluation in company-sponsored trials for treatment of refractory pediatric epilepsies—for this CMCR study, which is scheduled to start in 2019.

  • GlobeNewswire27 days ago

    INSYS Therapeutics to Report First Quarter 2018 Results on May 8

    PHOENIX, April 25, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release ...

  • Reuters28 days ago

    Ex-Insys employee in U.S. opioid case sentenced to home confinement

    A former Insys Therapeutics Inc sales representative was sentenced on Monday to six months of home confinement after admitting that she participated in a scheme to pay kickbacks to two Alabama doctors to prescribe a fentanyl-based medication. Natalie Perhacs, 32, was sentenced by U.S. District Judge Callie Granade in Mobile, Alabama, after pleading guilty to conspiring to pay kickbacks to the doctors to prescribe Insys' product Subsys, according to court records.

  • Investopedialast month

    Pot Stock Winners of the Week

    Here are the week's four biggest marijuana stock winners.

  • GlobeNewswirelast month

    INSYS Therapeutics to Advance Clinical Research of Dronabinol Inhalation Using Novel Breath-Actuated Device

    PHOENIX, April 18, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced plans to advance ...

  • Can Cannabis Treat Seizures? Biotechs Say The Answer Is Yes
    Investor's Business Dailylast month

    Can Cannabis Treat Seizures? Biotechs Say The Answer Is Yes

    GW Pharmaceuticals, Insys Therapeutics and Zynerba Pharmaceuticals are using cannabis-based therapies to treat a myriad of disorders, including seizures.

  • Better Marijuana Stock: 22nd Century Group vs. Insys Pharmaceuticals
    Motley Foollast month

    Better Marijuana Stock: 22nd Century Group vs. Insys Pharmaceuticals

    These two biotechs are big losers so far this year. But which has the better shot at being a winner over the long run?

  • Here's Why Insys Therapeutics Inc. Tanked 17% in March
    Motley Fool2 months ago

    Here's Why Insys Therapeutics Inc. Tanked 17% in March

    A handful of threats lobbed at opioid-based drugmakers pressured shares of the pain relief specialist following a dismal earnings report.